Avoro Capital Advisors LLC
Institutional investor · Portfolio as of Q1 2021
Top Holdings46 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
HORIZON THERAPEUTICS PLC | 9M | $828.4M | 14.3% | — | — | 8 qtrssince 2019-Q2 | Unchanged 0 |
MIRATI THERAPEUTICS INC | 4.7M | $800.8M | 13.8% | — | — | 9 qtrssince 2019-Q1 | Increased 65 |
UNITED THERAPEUTICS CORP | 3M | $501.8M | 8.7% | $149.52 | +10.67% | 2 qtrssince 2020-Q4 | Increased 65 |
ACCELERON PHARMA INC | 3M | $406.8M | 7.0% | — | — | 5 qtrssince 2020-Q1 | Increased 97 |
VERTEX PHARMACEUTICALS INC | 1.4M | $300.8M | 5.2% | $212.99 | 0.00% | 1 qtr | New 96 |
ARENA PHARMECEUTICALS INC | 4.1M | $281M | 4.9% | — | — | 4 qtrssince 2020-Q2 | Decreased 0 |
ARGENX SE - ADR | 925,500 | $254.9M | 4.4% | $135.60 | +103.09% | 9 qtrssince 2019-Q1 | Increased 59 |
IOVANCE BIOTHERAPEUTICS INC | 8M | $253.3M | 4.4% | $13.52 | +119.24% | 9 qtrssince 2019-Q1 | Increased 61 |
| 1.9M | $244.9M | 4.2% | $128.65 | +92.30% | 1 qtr | New 86 | |
MADRIGAL PHARMACEUTICALS INC | 1.4M | $166.7M | 2.9% | $117.71 | -1.02% | 9 qtrssince 2019-Q1 | Increased 61 |
AVI BIOPHARMA INC | 2.2M | $160.2M | 2.8% | $112.26 | -34.88% | 9 qtrssince 2019-Q1 | Increased 64 |
BIOMARIN PHARMACEUTICAL INC | 1.7M | $124.6M | 2.2% | $84.82 | -11.62% | 9 qtrssince 2019-Q1 | Unchanged 0 |
AMICUS THERAPEUTICS INC | 12.3M | $121M | 2.1% | $12.03 | -21.94% | 9 qtrssince 2019-Q1 | Increased 68 |
KURA ONCOLOGY INC | 4M | $113.1M | 2.0% | $28.23 | -5.74% | 4 qtrssince 2020-Q2 | Unchanged 0 |
MERSANA THERAPEUTICS INC | 6.8M | $110M | 1.9% | $553.14 | -30.80% | 4 qtrssince 2020-Q2 | Unchanged 0 |
ADVERUM BIOTECHNOLOGIES INC | 8M | $78.9M | 1.4% | — | — | — | — |
PMV PHARMACEUTICALS INC | 2.4M | $77.6M | 1.3% | $41.88 | -25.93% | 3 qtrssince 2020-Q3 | Increased 48 |
CONSTELLATION PHARMCETICLS I | 3M | $69M | 1.2% | — | — | 6 qtrssince 2019-Q4 | Unchanged 0 |
XENON PHARMACEUTICALS INC | 3.7M | $65.3M | 1.1% | $11.96 | +46.20% | 9 qtrssince 2019-Q1 | Increased 60 |
ACADIA Pharmaceuticals Inc. | 2.5M | $64.5M | 1.1% | $47.53 | -45.91% | 2 qtrssince 2020-Q4 | Increased 59 |
Avoro Capital Advisors LLC manages $5.8B across 46 positions as of Q1 2021. Top holdings: HZNP (14.3%), MRTX (13.8%), UTHR (8.7%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 3/5.0.
Active quarter - 7 new positions, 4 exits, 15 increased. Top move: XLRN (INCREASED, conviction 97). Portfolio: $5.8B across 46 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer